• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$20.00
+0 (0.00%)
Get New ArQule Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARQL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARQL

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for ArQule in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $20.00.

This chart shows the closing price for ARQL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in ArQule. This rating has held steady since December 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/10/2019B. RileyReiterated RatingBuy ➝ Neutral$14.00 ➝ $20.00Medium
12/10/2019Roth CapitalReiterated RatingBuy ➝ Neutral$20.00 ➝ $18.00Medium
12/10/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$16.00 ➝ $20.00Medium
12/10/2019HC WainwrightDowngradeBuy ➝ Neutral$13.00 ➝ $20.00Medium
12/10/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$12.00 ➝ $20.00Medium
12/9/2019Needham & Company LLCDowngradeBuy ➝ HoldMedium
11/27/2019B. RileyInitiated CoverageBuy$14.00Low
11/5/2019Wolfe ResearchInitiated CoverageOutperform$17.00Medium
10/17/2019Cantor FitzgeraldInitiated CoverageOverweight$16.00High
10/9/2019Royal Bank of CanadaSet TargetBuy$12.00N/A
9/16/2019HC WainwrightInitiated CoverageBuy$13.00Medium
7/11/2019OppenheimerSet TargetBuy$13.00Medium
6/19/2019Royal Bank of CanadaBoost TargetOutperform$12.00High
6/15/2019SVB LeerinkSet TargetBuy$12.00High
6/14/2019OppenheimerSet TargetBuy$11.00Medium
6/14/2019Roth CapitalBoost TargetBuy$10.00 ➝ $13.00High
6/5/2019OppenheimerSet TargetBuy$11.00High
5/29/2019B. RileyBoost TargetBuy$6.75 ➝ $11.00Medium
5/28/2019Roth CapitalReiterated RatingBuyMedium
5/2/2019Royal Bank of CanadaSet TargetBuy$10.00Medium
4/11/2019Royal Bank of CanadaInitiated CoverageOutperform$9.00High
3/8/2019B. RileySet TargetBuy$7.00Low
3/7/2019Roth CapitalSet TargetBuy$8.00High
3/7/2019OppenheimerSet TargetBuy$8.00High
12/2/2018Roth CapitalSet TargetBuy$7.00High
11/29/2018OppenheimerSet TargetBuy$7.00High
11/2/2018B. RileySet TargetBuy$7.00Low
11/1/2018Roth CapitalSet TargetBuy$7.00High
10/19/2018Roth CapitalSet TargetBuy$7.00High
8/8/2018B. RileySet TargetBuy$7.00Medium
6/29/2018B. RileyBoost TargetBuy ➝ Buy$4.00 ➝ $7.50High
6/18/2018Needham & Company LLCBoost TargetBuy$6.00 ➝ $7.00Low
6/12/2018OppenheimerInitiated CoverageOutperform$7.00High
5/8/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$5.00 ➝ $6.00Low
4/17/2018Roth CapitalBoost TargetBuy$5.00 ➝ $6.00High
4/5/2018SVB LeerinkUpgradeMarket Perform ➝ OutperformMedium
3/26/2018B. RileySet TargetBuy$4.00High
2/22/2018Roth CapitalInitiated CoverageBuy ➝ Buy$5.00 ➝ $5.00Medium
2/8/2018B. RileySet TargetBuy$3.00Low
2/2/2018B. RileyInitiated CoverageBuy ➝ Buy$3.00Low
12/14/2017Needham & Company LLCUpgradeHold ➝ BuyHigh
(Data available from 10/1/2017 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/4/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/4/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/3/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/3/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ArQule logo
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.
Read More

Today's Range

Now: $20.00
Low: $20.00
High: $20.00

50 Day Range

MA: $20.00
Low: $20.00
High: $20.00

52 Week Range

Now: $20.00
Low: $3.15
High: $20.45

Volume

N/A

Average Volume

5,269,080 shs

Market Capitalization

$2.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.49

Frequently Asked Questions

What sell-side analysts currently cover shares of ArQule?

The following Wall Street analysts have issued stock ratings on ArQule in the last twelve months:
View the latest analyst ratings for ARQL.

What is the current price target for ArQule?

0 Wall Street analysts have set twelve-month price targets for ArQule in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for ArQule in the next year.
View the latest price targets for ARQL.

What is the current consensus analyst rating for ArQule?

ArQule currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ARQL.

What other companies compete with ArQule?

How do I contact ArQule's investor relations team?

ArQule's physical mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company's listed phone number is 781-994-0300 and its investor relations email address is [email protected] The official website for ArQule is www.arqule.com. Learn More about contacing ArQule investor relations.